AAPL   318.75 (+0.16%)
FB   225.05 (-0.18%)
AMZN   2,414.63 (+0.56%)
NVDA   344.11 (+1.36%)
CGC   17.25 (-20.58%)
BABA   199.12 (-0.19%)
MU   46.71 (+0.52%)
TSLA   812.74 (+0.86%)
AMD   52.39 (+1.24%)
T   30.70 (-1.16%)
GILD   75.38 (+0.08%)
DIS   114.99 (-1.51%)
BAC   24.54 (-1.29%)
BA   145.11 (-3.14%)
AAPL   318.75 (+0.16%)
FB   225.05 (-0.18%)
AMZN   2,414.63 (+0.56%)
NVDA   344.11 (+1.36%)
CGC   17.25 (-20.58%)
BABA   199.12 (-0.19%)
MU   46.71 (+0.52%)
TSLA   812.74 (+0.86%)
AMD   52.39 (+1.24%)
T   30.70 (-1.16%)
GILD   75.38 (+0.08%)
DIS   114.99 (-1.51%)
BAC   24.54 (-1.29%)
BA   145.11 (-3.14%)
AAPL   318.75 (+0.16%)
FB   225.05 (-0.18%)
AMZN   2,414.63 (+0.56%)
NVDA   344.11 (+1.36%)
CGC   17.25 (-20.58%)
BABA   199.12 (-0.19%)
MU   46.71 (+0.52%)
TSLA   812.74 (+0.86%)
AMD   52.39 (+1.24%)
T   30.70 (-1.16%)
GILD   75.38 (+0.08%)
DIS   114.99 (-1.51%)
BAC   24.54 (-1.29%)
BA   145.11 (-3.14%)
AAPL   318.75 (+0.16%)
FB   225.05 (-0.18%)
AMZN   2,414.63 (+0.56%)
NVDA   344.11 (+1.36%)
CGC   17.25 (-20.58%)
BABA   199.12 (-0.19%)
MU   46.71 (+0.52%)
TSLA   812.74 (+0.86%)
AMD   52.39 (+1.24%)
T   30.70 (-1.16%)
GILD   75.38 (+0.08%)
DIS   114.99 (-1.51%)
BAC   24.54 (-1.29%)
BA   145.11 (-3.14%)
Log in

NASDAQ:MACKMerrimack Pharmaceuticals Dividend Yield, History & Payout Ratio

$3.28
-0.05 (-1.50 %)
(As of 05/29/2020 11:22 AM ET)
Add
Compare
Today's Range
$3.28
Now: $3.28
$3.40
50-Day Range
$3.34
MA: $3.57
$3.88
52-Week Range
$1.49
Now: $3.28
$7.09
Volume5,046 shs
Average Volume23,372 shs
Market Capitalization$43.89 million
P/E RatioN/A
Dividend YieldN/A
Beta2.49

Dividends


Merrimack Pharmaceuticals (NASDAQ:MACK) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
12/4/2019--$0.5012/13/201912/16/201912/23/2019
7/25/2019$1.49679/6/20198/28/20199/5/2019
4/7/2017Annual$10.605/30/20175/17/20175/26/2017
(Data available from 1/1/2013 forward)
This page was last updated on 5/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.